In addition to anti-EGFR antibodies, brigatinib can also be combined with the vascular endothelial growth factor (VEGF) inhibitor bevacizumab, in combination with osimertinib to effectively combat lung adenocarcinoma with EGFR L858R-T790M-cis C797S triple mutation (Figs. 3–4)[90]. Here, VEGFA is linked to lung adenocarcinoma.